02715nam 2200637Ia 450 991081613650332120240417004446.00-309-17747-21-282-00804-897866120080470-309-12868-4(CKB)1000000000755462(EBL)3378456(SSID)ssj0000206354(PQKBManifestationID)11187299(PQKBTitleCode)TC0000206354(PQKBWorkID)10214335(PQKB)10505895(MiAaPQ)EBC3378456(Au-PeEL)EBL3378456(CaPaEBR)ebr10280005(CaONFJC)MIL200804(OCoLC)923279910(EXLCZ)99100000000075546220090223d2009 uy 0engur|n|---|||||txtccrMulti-center phase III clinical trials and NCI cooperative groups workshop summary /Margie Patlak, Sharyl Nass, and Christine Micheel, rapporteurs ; National Cancer Policy Forum, Institute of Medicine of the National Academies1st ed.Washington, D.C. National Academies Press20091 online resource (135 p.)Description based upon print version of record.0-309-12867-6 Includes bibliographical references (p. 97-101).""Reviewers""; ""Contents""; ""Introduction""; ""Session 1A: Organization of the NCI Clinical Trials System""; ""Session 1B: Lessons from Non-Cooperative Group Multi-Center Clinical Trials""; ""Session 2: Barriers to Patient Recruitment and Physician Participation""; ""Session 3: Data Collection Standards and Monitoring""; ""Session 4: Costs of Cooperative Group Clinical Trials""; ""Summary and Wrap-Up""; ""References""; ""Abbreviations and Acronyms""; ""Glossary""; ""Appendix A: Workshop Agenda""; ""Appendix B: Workshop Speakers""""Appendix C: Letter from John Niederhuber, Director of the National Cancer Institute, to Members of the National Cancer Policy Forum""CancerTreatmentUnited StatesClinical trialsCancerTreatmentClinical trials.610.724Patlak Margie1607028Nass Sharyl J857626Micheel Christine1613229National Cancer Policy Forum (U.S.)Institute of Medicine (U.S.)MiAaPQMiAaPQMiAaPQBOOK9910816136503321Multi-center phase III clinical trials and NCI cooperative groups4127632UNINA